Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News FDA's Overreach on Compounded Peptides Triangle Compounding Pharmacy Inc, Cary, NC. 483 Issued 07 13 2017